![]()
|
EphedraUpdated April 19, 2004 Consumer Advisory The U.S. Food and Drug Administration (FDA) advises consumers to stop using dietary supplements containing ephedra. In order to protect consumers, the FDA published a final rule on April 12, 2004, that bans the sale of dietary supplements containing ephedrine alkaloids. After a careful review of the available evidence about the risks and benefits of ephedra in supplements, the FDA found that these supplements present an unreasonable risk of illness or injury to consumers. The data showed little evidence of ephedra's effectiveness, except for short-term weight loss, while confirming that the substance raises blood pressure and stresses the heart. The increased risk of heart problems and strokes negates any benefits of weight loss. What is ephedra? Ephedra is a naturally occurring substance that comes from botanicals. The principal active ingredient ephedrine is an amphetamine-like compound that can powerfully stimulate the nervous system and heart. Ephedrine alkaloids are found naturally in a number of plants, including the ephedra species (also known by the traditional Chinese medicine name--ma huang or Chinese Ephedra, or epitonin). In recent years, ephedra products have been marketed as dietary supplements to promote weight loss, increase energy, and enhance athletic performance. What evidence was collected to determine the safety and effectiveness of ephedra products? The FDA reviewed information about ephedra's pharmacology, studies of its safety and effectiveness, newly available adverse event reports, and the RAND Corporation report--a review of the published scientific literature on ephedra efficacy and safety, sponsored by NCCAM and the National Institutes of Health's Office of Dietary Supplements. In addition, the FDA considered additional recent studies confirming that ephedra use raises blood pressure and otherwise stresses the circulatory system. In February 2003, the agency solicited public comments regarding ephedra's side effects and whether ephedra-containing dietary supplements pose a "significant or unreasonable risk of illness or injury." NCCAM Ephedra Research In addition to supporting the RAND study, NCCAM supported a study of calls to poison control centers that revealed a disproportionate rate of reactions to ephedra relative to other herbal products. NCCAM will support to their completion two ongoing laboratory studies to better understand the mechanism of action and chemical properties of ephedra:
|